This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2019 Apr;121(3):380-381.

doi: 10.1016/j.acthis.2019.02.003. Epub 2019 Feb 20.

Braf-V600e immunohistochemical analyses in a series of 15, Caucasian patients affected by lentigo maligna

Affiliations

Affiliations

¹ Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy.
² Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy. Electronic address: mlambertini@hotmail.it.
³ Department of Pathology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
⁴ Laboratory of Oncologic Molecular Pathology, S.Orsola-Malpighi Hospital, Bologna, Italy.

PMID: 30797564
DOI: 10.1016/j.acthis.2019.02.003

Braf-V600e immunohistochemical analyses in a series of 15, Caucasian patients affected by lentigo maligna

Emi Dika et al. Acta Histochem. 2019 Apr.

. 2019 Apr;121(3):380-381.

doi: 10.1016/j.acthis.2019.02.003. Epub 2019 Feb 20.

Affiliations

¹ Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy.
² Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy. Electronic address: mlambertini@hotmail.it.
³ Department of Pathology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
⁴ Laboratory of Oncologic Molecular Pathology, S.Orsola-Malpighi Hospital, Bologna, Italy.

PMID: 30797564
DOI: 10.1016/j.acthis.2019.02.003

No abstract available

PubMed Disclaimer

Similar articles

The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.
Stadelmeyer E, Heitzer E, Resel M, Cerroni L, Wolf P, Dandachi N. Stadelmeyer E, et al. J Invest Dermatol. 2014 Feb;134(2):548-550. doi: 10.1038/jid.2013.338. Epub 2013 Aug 9. J Invest Dermatol. 2014. PMID: 24026210 No abstract available.
S100-negative junctional melanocytic proliferations.
Wilson ML, Hossler EW, Ferringer TC, Elston DM. Wilson ML, et al. Am J Dermatopathol. 2011 May;33(3):327-9. doi: 10.1097/DAD.0b013e3181e031d1. Am J Dermatopathol. 2011. PMID: 20940618 No abstract available.
Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins.
Magro CM, Yang SE, Zippin JH, Zembowicz A. Magro CM, et al. Arch Pathol Lab Med. 2012 Dec;136(12):1558-64. doi: 10.5858/arpa.2011-0617-OA. Arch Pathol Lab Med. 2012. PMID: 23194049 Free PMC article.
Lentigo Maligna.
Franke JD, Woolford KM, Neumeister MW. Franke JD, et al. Clin Plast Surg. 2021 Oct;48(4):669-675. doi: 10.1016/j.cps.2021.06.007. Epub 2021 Aug 5. Clin Plast Surg. 2021. PMID: 34503727 Review.
Amelanotic lentigo maligna melanoma.
Abeldaño AM, Saadi ME, Brea P, Kien MC, Chouela E. Abeldaño AM, et al. Skinmed. 2004 Jan-Feb;3(1):41-4. doi: 10.1111/j.1540-9740.2004.01996.x. Skinmed. 2004. PMID: 14724412 Review. No abstract available.

See all similar articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program